2020
Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy
Cheng H, Lopez V, Lam S, Leung A, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Molassiotis A. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health And Quality Of Life Outcomes 2020, 18: 246. PMID: 32703223, PMCID: PMC7376939, DOI: 10.1186/s12955-020-01493-y.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy/Gynecologic Oncology Group-NeurotoxicityFACT/GOG-Ntx subscalePatients treated with chemotherapyCancer patients treated with chemotherapyFACT/GOG-NtxAssessment pointsFunctional assessmentNational Cancer Institute Common Terminology CriteriaInternal consistency reliabilityPeripheral Neuropathy ScaleEORTC QLQ-CIPN20Longitudinal studyEuropean Organization for ResearchResultsCronbach’s alpha coefficientCommon Terminology CriteriaLight touch testMotor itemsLow-to-moderateConsistency reliabilityAlpha coefficientEvaluate CIPNQLQ-CIPN20Four-factor structurePsychometric analysisMonofilament test
2019
Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time
Wang M, Cheng H, Lopez V, Sundar R, Yorke J, Molassiotis A. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer 2019, 19: 1151. PMID: 31775665, PMCID: PMC6882224, DOI: 10.1186/s12885-019-6352-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCluster AnalysisFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPublic Health SurveillanceQuality of LifeSurveys and QuestionnairesSymptom AssessmentConceptsSymptom clustersCancer Quality of Life Questionnaire CoreTreatment of Cancer Quality of Life Questionnaire CoreQuality of Life Questionnaire CoreImprove symptom managementPatient-reported outcome dataBackgroundChemotherapy-induced peripheral neuropathySymptom management strategiesMethodsA secondary analysisSymptom cluster analysisNeurotoxic chemotherapy agentsEuropean Organization for the ResearchSymptom managementChemotherapy-induced peripheral neuropathySecondary analysisResultsSample sizeCancer diagnosisAssessment pointsPeripheral neuropathyOutcome dataCIPNClinical practiceThe ResearchFollow-upSecondary symptomsMinimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy
Yeo F, Ng C, Loh K, Molassiotis A, Cheng H, Au J, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Supportive Care In Cancer 2019, 27: 4753-4762. PMID: 30972646, DOI: 10.1007/s00520-019-04771-8.Peer-Reviewed Original ResearchConceptsMinimal clinically important differenceEORTC QLQ-CIPN20QLQ-CIPN20Clinically important differenceDistribution-based approachMotor subscaleNtx subscaleConclusionThe MCIDChange scoresSensory subscaleFunctional Assessment of Cancer Therapy/Gynecologic Oncology Group-NeurotoxicityImportant differenceStandard error of measurementFACT/GOG-NtxNeurotoxic chemotherapyExperience of symptomsAnchor-based approachError of measurementEuropean Organisation of ResearchDistribution-based methodsPeripheral neuropathyChemotherapy-induced peripheral neuropathyMethodsCancer patientsCycles of chemotherapyWorsening peripheral neuropathy